NSABP MEMBER: MICHIGAN STATE UNIVERSITY

密歇根州立大学癌症联盟(MSUCTC)由密歇根州立大学的社区校园以及全州的社区癌症项目组成，在密歇根州立大学主校区进行领导和协调。MSUCTC目前正在治疗和跟踪长期NSABP方案的1105名患者。方案的收益将继续增加四个机制：1)增加对目前活跃的社区肿瘤学家的科学和后勤支持；以及2)为MSUCTC招募更多的肿瘤学家和外科医生。我们的管理努力将集中在：1)增加NSABP主校区工作人员在我们广泛分布的社区(如肿瘤委员会、大型查房、医生和护理研讨会等)的活动中的存在；2)通过增加地方审计，为临床试验基础设施提供支持，以消除违反礼仪和减少违约率的行为；3)为MSU附属机构开发特定的NSABP网站；4)参与试点研究项目；5)一如既往，我们的团队将继续广泛参与NSABP的活动(如董事会、乳房委员会、结肠委员会、方案设计小组、审计小组和护理委员会的成员)。MSUCTC一直关注生活质量问题，因此，我们计划设计一项关于辅助治疗认知影响的先导性研究，作为更大规模的NSABP试验的模型。此外，我们将在密歇根州的美国原住民社区中进行一项关于接受和遵守NSABP协议的研究，这将帮助该组织设计一项战略，以实现这一群体的收益。我们的机构有一个特殊的计划，由NIH补充拨款支持，促进和监测少数民族对NSABP试验的应计收入。这一经验将传达给NSABP。拥有完善的实验室，配备高效液相、气相色谱和质谱仪，我们机构将为该团队提供与药物和激素代谢物相关的额外研究。最近，密歇根州立大学成立了一个强大的小组，开发靶向治疗。在化疗期间(包括使用替代组织)，我们检测到了MAP-Kinase的实质性变化，这将作为在执行NSABP方案期间设计先导性研究的基础。我们正在为患者准备B-30方案的试点方案，该方案将提交NSABP批准。密歇根州立大学的一个跨学科小组正在研究细胞周期调控基因和基因产物的相互关系和联系，以及它们对肿瘤从非侵袭性(DCIS)到侵袭性和转移性疾病发展的影响。这可能有助于预测生物学行为和治疗反应。这两个研究领域相辅相成，可能有助于该小组设计具有药物基因组元素的方案。

The Michigan State University Cancer Consortium (MSUCTC) consists of the community campuses of MSU along with community cancer programs across the state, with leadership and coordination at the main MSU campus. The MSUCTC is currently treating and following 1,105 patients on long-term NSABP protocols. Accrual to protocols will continue to increase by four mechanisms: 1) Increasing the scientific and logistic support for currently active community oncologists; and 2) Recruitment of additional oncologists and surgeons to the MSUCTC. Our administrative efforts will focus on: 1) Increasing the presence of the main campus NSABP staff in the activities of our widely dispersed communities (e.g., tumor boards, grand rounds, physicians and nursing seminars, etc.); 2) Clinical trials infrastructural support by increasing local audits in order to eliminate protocol violations and decrease delinquencies; 3) Development of a specific NSABP web site for MSU affiliates; 4) Participation in pilot research projects; 5) As in the past, our group will continue to participate extensively in the NSABP activities (PI member of the board, breast committee, colon committee, protocol design group, audit group, and nursing committee. The MSUCTC has been concerned about quality of life issues, therefore, our plans are to design a pilot study of the cognitive effects of adjuvant therapy which will serve as a model for a larger NSABP trial. In addition, we will be conducting a study of acceptance and compliance with NSABP protocols in Native American communities in Michigan which will help the group design a strategy for approach to accrual of this population. Our institution has a special program to foster and monitor accrual of ethnic minorities to NSABP trials supported by NIH supplemental grants. This experience will be conveyed to the NSABP. Having a well-developed laboratory, equipped with HPLC, GLC, and Mass Spectroscopy apparatuses, our institution will offer to the group additional studies related to drug and hormone metabolites. Recently, MSU has formed a strong group developing targeted therapy. We have detected substantial changes in MAP-kinases during chemotherapy (including use of surrogate tissues) which will serve as a basis for designing pilot studies during the execution of NSABP protocols. We are in the process of preparation of a pilot protocol with patients on protocol B-30 which will be submitted to the NSABP for approval. An interdisciplinary group at MSU is studying the interrelations and abberations of cell cycle regulatory genes and gene products and their effect on tumor progression from non-invasive (DCIS) to invasive and metastatic disease. This may help to predict biologic behavior as well as treatment response. These two areas of research complement each other and may help the group design protocols with pharmacogenomic elements.